Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated)
Authors:
- Akiko KikukawaAKAkiko Kikukawa
- Yasuyuki GomiYGYasuyuki Gomi
- Masateru AkechiMAMasateru Akechi
- Toshiyuki OnishiTOToshiyuki Onishi
- Sadao ManabeSMSadao Manabe
- Junko NamazueJNJunko Namazue
- Isao FukeIFIsao Fuke
- Toyokazu IshikawaTIToyokazu Ishikawa
- Yoshinobu OkunoYOYoshinobu Okuno
- Shigeharu UedaSUShigeharu Ueda
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- New Japanese encephalitis vaccines: alternatives to production in mouse brainExpert Review of Vaccines, 2011
- IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccineExpert Review of Vaccines, 2010
- WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1–2 June 2006Vaccine, 2007
- Control of Japanese Encephalitis — Within Our Grasp?New England Journal of Medicine, 2006
- Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004Vaccine, 2005
- Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccinesVaccine, 2000
- Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strainsVaccine, 2000
- Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains).Journal of Neurology, Neurosurgery & Psychiatry, 1995
- Acute disseminated encephalomyelitis after Japanese B encephalitis vaccinationPediatric Neurology, 1992
- Japanese Encephalitis VaccinePediatrics International, 1988